Detection of parvovirus B19 DNA in solvent–detergent plasma

Just, Burkhard; Lefèvre, Hans

doi:10.1046/j.1423-0410.2002.00204.x

Cited by 6 publications

(4 citation statements)

References 2 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several plasma derivatives are prepared from large plasma pools. A substantial number of these manufacturing pools contain B19V DNA 7‐9 . This can be explained by the relatively high incidence of B19V infection among blood donors 10,11 and the high level of viremia (up to 10 14 virions/mL) during onset of B19V infection 12 …”

Section: Maximum Acceptable Levels Of B19v Dna In Plasmamentioning

confidence: 99%

Quantitative real‐time detection of parvovirus B19 DNA in plasma

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Maximum Acceptable Levels Of B19v Dna In Plasmamentioning

confidence: 99%

Quantitative real‐time detection of parvovirus B19 DNA in plasma

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Unlike factors VIII and IX, albumin has not transmitted parvovirus B19. [82][83][84][85][86][87][88] One report implicated parvovirus transmission by IVIG based on detection of viral DNA by PCR. 89 However, no documentation showed the same viral genotype in the recipient and the immunoglobulin preparation.…”

Section: Transmission By Transfusionmentioning

confidence: 99%

Other Viral, Bacterial, Parasitic and Prion-Based Infectious Complications

Menitove¹,

Tegtmeier²

2007

Blood Banking and Transfusion Medicine

View full text Add to dashboard Cite

“…AT levels show good negative correlation to prognosis in, for example, sepsis and disseminated intravascular coagulation (DIC) [2]. Acquired AT deficiency occurs as a result of either decreased production, i.e.…”

mentioning

confidence: 99%

“…Sterilization techniques [e.g. Solvent/Detergent (S/D), heat, and photoactivated methylene blue] have improved the safety of plasma and plasma derivatives, but also have drawbacks [1–4]. Newer methods (e.g.…”

mentioning

confidence: 99%

Cascade iodination: a novel method to enhance the safety and efficacy of therapeutic proteins

Shanbrom

2004

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

administration of rituximab causes depletion of B cells expressing the surface antigen CD20. The mechanism of cell killing is thought to be secondary to antibody-dependent cellular toxicity and complement activation. Suppression of autoreactive B cells may explain the sustained response attained when using rituximab in the treatment of lymphomas and autoimmune disorders [3,4].In this report, four of five patients achieved durable remission confirming the successful outcome using rituximab in refractory TTP recently reported by other investigators [5][6][7]. The dose and frequency of administration of rituximab in the current series is based on the experience in the treatment of non-Hodgkin's lymphoma. The time to recovery of platelet counts in our patients is consistent with the results observed in patients with idiopathic thrombocytopenic purpura [4]. All patients in that study received rituximab in a dose and frequency similar to the current series.Because of the limited available experience in the treatment of TTP with rituximab, it is difficult to make direct comparison with the results obtained from other investigators [5][6][7]. For example, one patient with chronic relapsing TTP achieved a rather short remission with two doses and a sustained remission after four infusions of rituximab [6]. In another case, full recovery of platelet count and durable remission was achieved after only two doses of rituximab [5]. Therefore, the number of doses of rituximab required to achieve response in patients with refractory TTP is worth addressing in future trials. It is also important to emphasize that PLEX was used on a daily basis in our patients until platelet recovery. Unfortunately, no information is currently available on whether rituximab is removable by PLEX. As plasma levels of rituximab were not measured in this group of patients, it is difficult to assess the impact of PLEX on the efficacy of rituximab. As would be expected intuitively, durable remission correlated well with recovery of VWF-CPA and resolution of the inhibitor. The duration and type of treatment previously administered did not influence the response to rituximab in this study. However, it is important to note that the non-responder in our series had an underlying condition (malignancy) that typically does not respond well to PLEX and other therapeutic strategies.In summary, rituximab is potentially an effective and well tolerated agent in patients with refractory TTP. The frequency of infusion and sequence of administration, i.e. immediately after failure of PLEX or following splenectomy should be further investigated.

show abstract

Detection of parvovirus B19 DNA in solvent–detergent plasma

Cited by 6 publications

References 2 publications

Quantitative real‐time detection of parvovirus B19 DNA in plasma

Quantitative real‐time detection of parvovirus B19 DNA in plasma

Other Viral, Bacterial, Parasitic and Prion-Based Infectious Complications

Cascade iodination: a novel method to enhance the safety and efficacy of therapeutic proteins

Contact Info

Product

Resources

About